ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis

Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritisINDIANAPOLIS, Nov. 12, 2019 -- (Healthcare Sales & Marketing Network)-- Eli Lilly and Company (NYSE: LLY) announced today the 52-w...Biopharmaceuticals
Eli Lilly, Taltz, ixekizumab, psoriatic arthritis